The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) and GlaxoSmithKline have entered a public-private partnership agreement to develop drugs to combat bioterrorism and antibiotic resistance. “Working as strategic partners with a portfolio approach offers a new way to move forward in developing a robust pipeline of novel antibiotics that address gaps in our nation’s preparedness as well as the evolving threat of antibiotic resistance,”...